Make Insulin Affordable

“Insulin’s High Cost Leads To Lethal Rationing” – NPR

Such a tragic story of a young man’s life cut short because he couldn’t afford his insulin. Sign the ADA Petition to make insulin affordable.

We can make a difference starting today! 

Make Insulin Affordable – what you can do today

 

We are excited to share our NEW Part 4 of our FREE Medication Quiz series:

Test your medication knowledge with our four complimentary quizzes. We designed these medication quizzes to give you a feel for the medication questions on the exam and also to keep you up to date on medication updates in Diabetes.

Free Medication Quiz Part 1

Free Medication Quiz Part 2

Free Medication Quiz Part 3

NEW Free Medication Quiz Part 4


For other FREE resources, check out our FREE Resource Catalog:

FREE Resource Catalog

Featuring our downloadable Medication PocketCards, 10 Steps to Succeed, Free Webinars and more! 

You can now sign up to receive our blog posts in your inbox – Click here to sign up.

 

 

 

According to a statement made recently by Eli Lilly, they have submitted a nasal glucagon treatment to the FDA. The treatment would be for cases of severe hypoglycemia in adults and children with diabetes. This treatment would be the first of it’s kind, a nasal spray, to treat low blood glucose emergencies in those with diabetes.  

“The submissions put us one step closer to bringing this innovative rescue medicine to the diabetes community and filling an important need in the treatment of severe hypoglycemia,” said Thomas Hardy, Senior Medical Director, Lilly Diabetes, told Endocrine Today. 

The way glucagon is currently administered can be a complicated process, requiring the administer to reconstitute the powder and other steps. This can be a confusing process, particularly if you are a caregiver a a child with diabetes. The new nasal glucagon would deliver the medicine in a powder form in an easy, ready to use format. Many people already understand how to use nose spray, making this functional but also realistic in a hypoglycemic emergency. 

 “This is important and different. You don’t want people to get low [blood sugar], but they do. It’s not a pretend problem, and the fact that the science is clear that people don’t know how to treat it makes it a real problem. With this nasal glucagon kit, anyone could rescue them.”

To learn more about the new nasal glucagon – Lilly submits NDA for nasal glucagon by Helio Endocrine Today

 

Updated and now available On Demand in the Online University

This course is included in: Level 2 – Beyond Fundamentals. Purchase this course individually for $29 or the entire bundle and save 70%. 

Diabetes Education Services Online University Courses are an excellent way to study for your exam anytime and anywhere that is convenient for you. You will have immediate access to your courses  for 1 year after your purchase date. Each individual online course includes a: 90 minute video presentation, podcast, practice test and additional resources.

This advanced level course is designed to help participants determine the best medication choice based on the patient’s unique characteristics. The content incorporates the management guidelines published by the American Association of Clinical Endocrinologists (AACE) and the American Diabetes Association (ADA) Algorithms. We will discuss the role of lifestyle changes and review the pros and cons of available diabetes medications using a patient centered approach. In addition, we discuss the medication algorithms in detail. Participants not familiar with the basics of diabetes medication, may benefit from first enrolling in our “Meds for Type 2” and “Insulin 101 Course.”  90-minute course.


Topics include:

  • The importance of patient assessment in determining a realistic meds management plan.
  • Gain insights into developing an individualized plan to treat hyperglycemia in collaboration with the person with diabetes
  • Strategies on adjusting meds plus lifestyle to achieve glucose targets

Intended Audience:  A great course for health care professionals seeking to enhance their knowledge of hyperglycemia management for those living with type 2 diabetes.

Instructor: Beverly Thomassian RN, MPH, CDE, BC-ADM is a working educator and a nationally recognized diabetes expert.

Fee: $29.00 (Group Discounts Available)

Course Level: 2 (included in Level 2 – Beyond Fundamentals)

All hours earned count toward your CDE Accreditation Information

Earn 1.5 CEs

Video presentation and podcast available now On Demand.

*Certified Diabetes Educator® and CDE® are registered marks owned by NCBDE. The use of DES products do not guarantee successful passage of the CDE® exam. NCBDE does not endorse any preparatory or review materials for the CDE® exam, except for those published by NCBDE.”

New & Update Medication Update Webinar is now available! 

Feeling overwhelmed by all the new recently approved diabetes medications? Two bio-similiar insulins are now available and another GLP-1 RA was just approved. Plus, 2 new combo oral meds are now available.

Are you wondering how to apply the new 2018 ADA and AACE Medication Management Guidelines into practice?

We are here to help out with our newly recorded Medication Update 2018!

This webinar will discuss how to integrate these new medications into our practice. We will discuss the benefits and limitations and critical information to share with our patients and providers. If you want cutting edge information on the latest pharmacology and hospital glucose management, we highly recommend this Meds Update.

 

Testimonial: I want to let you know your online program rocks! I’d say it is the best one out there!”  – Marsha

Fee: $29.00 (Group Discounts Available)

All hours earned count toward your CDE Accreditation Information

All video presentations and podcasts available now On Demand. Includes both courses, free podcasts, handouts, resources and CE Certificates.  

Standards of Care Section 8 – Approaches to Glycemic Treatment

Insulin Therapy for Type 1
This updated version of Meds Management includes more detailed information on insulin therapy for Type 1s. They note that sensor-augmented insulin pump therapy with the threshold suspend feature reduced nocturnal hypoglycemia without increasing A1c (for type 1s in a 3 month randomized trial). The FDA approved the first hybrid closed-loop pump system, since the literature supports its safety and efficacy.

Investigational Agents for Type 1s

  • Add on Metformin for Type 1 – In several trials, adding metformin to insulin for type 1s, reduced insulin requirements 6.6 units a day and led to small reductions in weight and LDL cholesterol. However, it did not significantly reduce A1c. Metformin in not FDA Approved for use in patients with type 1 diabetes.
  • SGLT-2 Inhibitors – these “glucoretics” lower glucose by decreasing renal reabsorption of glucose in the proximal tubules. Since this class works independent of endogenous insulin, SGLT-2 Inhibitors may benefit patients with type 1 or type 2 (not FDA Approved for use in patients with type 1 diabetes).  However, the FDA has issued a warning of the risk of ketoacidosis occurring in the absence of significant hyperglycemia. There are many reported cases of euglycemic ketoacidosis in patients with type 1 or type 2 diabetes. If patients are experiencing signs of ketosis, instruct them to immediately stop taking the SGLT-2 and seek immediate care.

Type 2 Management Strategies – Stepwise Approach to Pharmacologic Management of Type 2 Diabetes – 2018

Pharmacologic Approaches to Glycemic Treatment 2018.  This hyperglycemia road map details strategies to achieve glucose control for both Type 1 and Type 2 Diabetes. Section 8 of Standards of Care, Dec 2018.

Step 1

According to the ADA 2018 Standards, section 8, Metformin therapy should be started along with lifestyle Management at diagnosis of type 2 Diabetes (unless contraindicated). Metformin is effective, safe, inexpensive and may reduce risk of CV events and death.

Step 2

If A1c target is not achieved after 3 months, consider metformin and any one of the six preferred treatment options based on drug specific effects and patient factors.

If A1c target is still not achieved after 3 months on metformin, and the patient has CV Disease, consider adding a second agent with evidence of cardiovascular risk reduction (based on drug specific effects and patient factors).

These include:

  • SGLT-2 Inhibitors – empalgliflozin (Jardiance) and canagliflozin (Invokana)
  • GLP-1 Receptor Agonist – liraglutide (Victoza)

Step 3

If A1c target is still not achieved after 3 months, combine metformin plus two other agents for a three-drug combination.

Step 4  

If A1c target is still not achieved after 3 months, add combination injectable therapy to the three-drug combination.

For all steps, consider including medications with evidence of CV risk reduction, based on drug specific effects and patient factors.

Medication Therapy Based on A1c

  • If A1c is less than 9%, consider monotherapy
  • If A1c is greater than or equal to 9% consider dual therapy
  • If A1c is greater or equal to 10%, or if BG 300 or more, or pt is markedly symptomatic, consider insulin and injectable therapy.

Want to learn more about this topic?

 


 

 

New SGLT-2 Inhibitor – Ertugliflozin

The Food and Drug Administration (FDA) has approved Ertugliflozin (Steglatro), a new SGLT-2 Inhibitor to treat adults with type 2 diabetes. Also approved are two new combination medications with ertugliflozin.  These include Segluromet (ertugliflozin plus metformin) and Steglujan (ertugliflozin plus sitagliptin). See box below for available combination doses (in mgs).

Dosing range: 5 -15 mg daily.  Monitor GFR before starting. Don’t start med if GFR is less than 60 and stop if GFR is less than 30.

Considerations: Ertugliflozin has the same warnings as other SGLT-2s: Watch for hypotension, UTI’s, increased urination, genital infections, ketoacidosis.

Benefits: no hypoglyecmia or weight gain.
Lowers A1c 1.0% – 2.0%. Lowers wt 1-3 lbs.

Download our FREE Updated Insulin PocketCard


Medication Update Webinar – Feb 19, 2018 11:30 to 1pm (PST)

Feeling overwhelmed by all the new recently approved diabetes medications? Two bio-similiar insulins are now available and another GLP-1 RA was just approved. Plus, 2 new combo oral meds are now available.

Are you wondering how to apply the new 2018 ADA and AACE Medication Management Guidelines into practice?

We are here to help out!

This webinar will discuss how to integrate these new medications into our practice. We will discuss the benefits and limitations and critical information to share with our patients and providers.

If you want cutting edge information on the latest pharmacology and how to incorporate the new ADA Guidelines into practice, we highly recommend this Meds Update.

To Join Us and earn CEs you have 2 options: 

med3

diabetesed-buynow2-150x28-1

Or Purchase our Meds Update Toolkit

Earn 3.5 CE’s – 2 Courses for Only $49

This toolkit includes:

  • Meds Update Course 2018 – cutting edge information on the latest pharmacology and how to incorporate the new ADA Guidelines into practice.
  • Basal-bolus Insulin in the Hospital Setting Course – A comprehensive program which explores the effective use of basal bolus insulin in the hospital setting through case studies and examples.

If you want cutting edge information on the latest pharmacology and hospital glucose management, we highly recommend this Meds Update Toolkit.

diabetesed-buynow2-150x28-1

 


 

New Copycat Bolus Insulin

The Food and Drug Administration (FDA) has approved Admelog (Sanofi-Adventis US), the first copycat version of short-acting insulin lispro (Humalog, Eli Lilly)  to treat individuals aged 3 years and older with type 1 diabetes and adults with type 2 diabetes.

Download our FREE Updated Insulin PocketCard

Features:

Approved for use as an injection, via pump, or intravenously.

It will be available both in vials and as a prefilled pen (Admelog SoloStar).

The FDA approved Admelog through an abbreviated approval pathway under which companies can rely on the FDA’s previous approval of a drug as safe and effective or on previously published literature supporting safety and/or effectiveness. This process is meant to reduce drug development costs in order to reduce the drug’s price on the market.

 


Medication Update Webinar – Feb 19, 2018 11:30 to 1pm (PST)

Feeling overwhelmed by all the new recently approved diabetes medications? Two bio-similiar insulins are now available and another GLP-1 RA was just approved. Plus, 2 new combo oral meds are now available.

Are you wondering how to apply the new 2018 ADA and AACE Medication Management Guidelines into practice?

We are here to help out!

This webinar will discuss how to integrate these new medications into our practice. We will discuss the benefits and limitations and critical information to share with our patients and providers.

If you want cutting edge information on the latest pharmacology, we highly recommend this Meds Update.

To Join Us and earn CEs you have 2 options: 

med3

diabetesed-buynow2-150x28-1

Or Purchase our Meds Update Toolkit

Earn 3.5 CE’s – 2 Courses for Only $49

This toolkit includes:

  • Meds Update Course 2018 – cutting edge information on the latest pharmacology and how to incorporate the new ADA Guidelines into practice.
  • Basal-bolus Insulin in the Hospital Setting Course – A comprehensive program which explores the effective use of basal bolus insulin in the hospital setting through case studies and examples.

If you want cutting edge information on the latest pharmacology and hospital glucose management, we highly recommend this Meds Update Toolkit.

diabetesed-buynow2-150x28-1

 


 

New GLP-1; Semaglutide (Ozempic)

The US Food and Drug Administration (FDA) has approved semaglutide (Ozempic, Novo Nordisk) as an adjunct to diet and exercise for the treatment of type 2 diabetes in adults.

This once weekly injection of (GLP-1) receptor agonist will be available in 0.5-mg and 1.0-mg doses, via a dedicated prefilled pen device. 

Semaglutide is the seventh GLP-1 receptor agonist on the US market and the third dosed once weekly.
And the data suggests it might be more effective than some of its competitors. 

Download our updated FREE Injectables PocketCard

Features:

The company’s eight phase 3a trials involved over 8000 adults with type 2 diabetes, including individuals at high cardiovascular risk and those with renal disease. One of the studies, SUSTAIN-6, was a 2-year FDA-mandated cardiovascular-outcomes trial involving 3297 patients.

  • In the five SUSTAIN efficacy trials, semaglutide reduced hemoglobin A1c by 1.5 to 1.8 percentage points.
  • Semaglutide was also associated with a 4.5- to 6.4-kg weight loss. The most common side effect was mild to moderate nausea, which diminished over time.

 

After approval, Novo Nordisk is required to conduct a pediatric trial in adolescents younger than 18 years of age and to add semaglutide to a 15-year medullary thyroid carcinoma registry that includes all of the long-acting GLP-1 products.  

Semaglutide will be priced similarly to current weekly GLP-1 receptor agonists and will be offered with a savings card program to reduce copays for eligible commercially insured patients.


Medication Update Webinar – Feb 19, 2018 11:30 to 1pm (PST)

Feeling overwhelmed by all the new recently approved diabetes medications? Two bio-similiar insulins are now available and another GLP-1 RA was just approved. Plus, 2 new combo oral meds are now available.

Are you wondering how to apply the new 2018 ADA and AACE Medication Management Guidelines into practice?

We are here to help out!

This webinar will discuss how to integrate these new medications into our practice. We will discuss the benefits and limitations and critical information to share with our patients and providers.

If you want cutting edge information on the latest pharmacology and hospital glucose management, we highly recommend this Meds Update.

To Join Us and earn CEs you have 2 options: 

med3

diabetesed-buynow2-150x28-1

Or Purchase our Meds Update Toolkit

Earn 3.5 CE’s – 2 Courses for Only $49

This toolkit includes:

  • Meds Update Course 2018 – cutting edge information on the latest pharmacology and how to incorporate the new ADA Guidelines into practice.
  • Basal-bolus Insulin in the Hospital Setting Course – A comprehensive program which explores the effective use of basal bolus insulin in the hospital setting through case studies and examples.

If you want cutting edge information on the latest pharmacology and hospital glucose management, we highly recommend this Meds Update Toolkit.

diabetesed-buynow2-150x28-1

 


 

Bydureon BCise Injector

The once weekly GLP-1 Receptor Agonist, Bydureon, is a dual chambered pen that requires mixing and assembly that was challenging for some patients.

Download our FREE Updated Insulin PocketCard

To improve the patient experience, a new extended release pre-filled delivery device, Bydureon BCise – has been approved by the FDA. for adults with type 2 diabetes. The new autoinjector features a simpler mixing process, a hidden needle, and a viewing window for users to confirm that they’ve received the medication.

Features of Bydureon BCise (rhymes with “precise”) is expected to launch in early 2018.

  • Easier mixing: To prep the BCise pen for injection, the user simply has to shake it for 15 seconds. By comparison, the older dual-chambered pen instructed users to tap it “80 times or more.”

  • Pre-attached needle: With the dual-chambered pen, users had to screw on the needle cap. Bydureon BCise comes with a hidden needle.

  • Easier injection: To administer Bydureon BCise, users are directed to push the pen against the skin and hold for 15 seconds, removing the hassle of needle insertion and holding down the plunger.

To get the new autoinjector, healthcare professionals must write a prescription specifically for Bydureon BCise. AstraZeneca has not specified what the price of Bydureon BCise beyond suggesting that it will be comparable to the dual-chambered pen pricing.


Medication Update Webinar – Feb 19, 2018 11:30 to 1pm (PST)

Feeling overwhelmed by all the new recently approved diabetes medications? Two bio-similiar insulins are now available and another GLP-1 RA was just approved. Plus, 2 new combo oral meds are now available.

Are you wondering how to apply the new 2018 ADA and AACE Medication Management Guidelines into practice?

We are here to help out!

This webinar will discuss how to integrate these new medications into our practice. We will discuss the benefits and limitations and critical information to share with our patients and providers.

If you want cutting edge information on the latest pharmacology and hospital glucose management, we highly recommend this Meds Update.

To Join Us and earn CEs you have 2 options: 

med3

diabetesed-buynow2-150x28-1

Or Purchase our Meds Update Toolkit

Earn 3.5 CE’s – 2 Courses for Only $49

This toolkit includes:

  • Meds Update Course 2018 – cutting edge information on the latest pharmacology and how to incorporate the new ADA Guidelines into practice.
  • Basal-bolus Insulin in the Hospital Setting Course – A comprehensive program which explores the effective use of basal bolus insulin in the hospital setting through case studies and examples.

If you want cutting edge information on the latest pharmacology and hospital glucose management, we highly recommend this Meds Update Toolkit.

diabetesed-buynow2-150x28-1